TRAILR2/TNFRSF10B Antibody

Product Specs
ItemTRAILR2/TNFRSF10B Antibody - BSA Free
CompanyNovus Biologicals, a Bio-Techne Brand
Price $419.00Supplier Page View Company Product Page
Catalog NumberNB100-56618
Quantity0.1 mg (also 0.025 mg)
ApplicationsIF/IHC,Flow Cytometry,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Flow (Cell Surface),Immunocytochemistry/ Immunofluorescence
Concentration1.0 mg/ml
Conjugate/TagUnconjugated
FormatPBS
PurityProtein G purified
ReactivityHuman,Mouse
TargetTRAILR2/TNFRSF10B
HostRabbit
IsotypeIgG
Antibody TypePrimary Antibodies
ImmunogenRabbit anti-DR5 polyclonal antibody was raised against a peptide corresponding to amino acids 388 to 407 (isoform 2) of human DR5 precursor (1,2). The same sequence is found in isoform 1 at amino acids 417-436
ClonalityPolyclonal
Research AreaApoptosis, Cancer, Death Receptor Signaling Pathway
StorageStore at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles
NCBI Full Gene NameTNF receptor superfamily member 10b
NCBI Gene AliasesCD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9

Specifications/Features

Available conjugates: Unconjugated

Add to Compare List

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: https://www.novusbio.com

(1) Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinomaScientific reportsJuly 14, 2023Haagsma J, Kolendowski B, Buensuceso A, Valdes YR, DiMattia GE, Shepherd TG.was purchased from Calbiochem. Antibodies against Trail (CAT# NB500-220; 1:1000) and Trailr2 (CAT# NB100-56618; 1:1000) were purchased from Novus Bio. Antibodies against actin (CAT# A2066; 1:20,000) and vinculin

(2) CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicityNature communicationsMarch 25, 2022Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, et al.(Santa Cruz Biotechnology sc-8009, 1:200), IFNAR1 (Santa Cruz Biotechnology sc-7391, 1:100), TNFRSF10B (Novus Biologicals NB100-56618, 1:200), MICB (R&D Systems MAB1599-100, 1:500), TNFRSF10A (R&D Systems AF347, 1:200), PVR (R&D Systems

(3) Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulationThe Journal of biological chemistryJanuary 1, 2021Chen L, Hao M, Yan J, Sun L, Tai G, Cheng H, Zhou Y.with 2% FBS/PBS. The cells were labeled with anti-DR4 (NB100-56747, Novus Biologicals) or anti-DR5 (NB100-56618, Novus Biologicals) antibody for 20 min on ice and then incubated with phycoerythrin-conjugated secondary

(4) Biological activity of weekly ONC201 in adult recurrent glioblastoma patientsNeuro-oncologyJanuary 11, 2020Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, et al.sc-5303), DRD5 (Atlas, HPA048930), activating transcription factor 4 (ATF4) (Abcam, ab184909), DR5 (Novus, NB100-56618), and terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) (Novus,

(5) Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administrationJournal for immunotherapy of cancerMay 22, 2019Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, et al.described (Diapharma; #P10011) [15]. Immunohistochemistry for CHOP (Proteintech; # 5204–1-AP), DR5 (Novus; NB100–56618), CD56 (BioLegend, Catalog X), Granzyme B (Abcam; Catalog X) and TUNEL (Novus; #NBP2–31164) was carried

(6) Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathwaysMolecular medicine reportsJuly 1, 2017Xue M, Ge Y, Yu C, Zheng Z, He X, Zhao J.

(7) Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL responseAutophagyDecember 1, 2016Shin GC, Kang HS, Lee AR, Kim KH.

(8) Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse ModelsClinical cancer research : an official journal of the American Association for Cancer ResearchDecember 1, 2015Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

(9) ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cellsCell cycle (Georgetown, Tex.)August 3, 2015Talekar MK, Allen JE, Dicker DT, El-Deiry WS.

(10) NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5International journal of oncologyAugust 1, 2015Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF.

(11) Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent MannerCancer researchApril 1, 2015Prabhu VV, Allen JE, Dicker DT, El-Deiry WS.

(12) First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer AgentPloS oneJanuary 1, 2015Allen JE, Crowder RN, El-Deiry WS.

(13) H-Ras regulation of TRAIL death receptor mediated apoptosisOncotargetJuly 15, 2014Chen JJ, Bozza WP, Di X, Zhang Y, Hallett W, Zhang B.

(14) The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signalingCell cycle (Georgetown, Tex.)January 1, 2014Xu J, Zhou JY, Xu Z, Kho DH, Zhuang Z, Raz A, Wu GS.

(15) Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapyScientific reportsDecember 20, 2013Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J, Hua ZC.

(16) Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosisThe Journal of biological chemistryNovember 15, 2013Xu J, Xu Z, Zhou JY, Zhuang Z, Wang E, Boerner J, Wu GS.

(17) Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5OncotargetSeptember 1, 2013Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado LA, Zhang B.

(18) Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axisPloS oneJanuary 1, 2013Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS.

(19) Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesMolecular cancer therapeuticsOctober 1, 2012Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS.

(20) Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathwaysInvestigative ophthalmology & visual scienceAugust 9, 2011Zhang X, Chen W, De Paiva CS, Corrales RM, Volpe EA, McClellan AJ, Farley WJ, Li DQ, Pflugfelder SC.

Be the First to Write a Review!